Results 241 to 250 of about 137,029 (384)

Infliximab licensing expands to include halting arthritis progression [PDF]

, 2001
Cheryl A. Thompson
openalex   +1 more source

Systemic Biologics Have Similar Safety to Vedolizumab in Inflammatory Bowel Disease Patients Following Liver Transplantation

Alimentary Pharmacology &Therapeutics, EarlyView.
In liver transplant recipients with coexistent inflammatory bowel disease, incidence of infectious events observed between those exposed to ‘gut‐specific’ and ‘systemic’ biologics were similar. Biologic choice should not be influenced by concerns regarding their co‐prescription with transplant immunosuppression.
Simone Chin, Danny Con, Patrick Hilley, Crispin Corte, Ken Liu, Adam Testro, Peter De Cruz, Matthew C. Choy, Ashish Srinivasan   +8 more
wiley   +1 more source

Frequency of tuberculosis in psoriasis patients using anti-TNF therapy during 16 years of follow-up. [PDF]

Postepy Dermatol Alergol
Mert Ö, Güneş B, Güler Filiz B, Onsun N.   +3 more
europepmc   +1 more source

Treatment of ankylosing spondylitis with infliximab [PDF]

, 2001
C A BOEGER
openalex   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Prolonged Duration of Response to Infliximab in Early Pediatric Crohnʼs Disease

, 2001
Subra Kugathasan
openalex   +1 more source

Infliximab-dependência

GE Jornal Português de Gastrenterologia, 2012
openaire   +3 more sources

Dental Implant Therapy in Patients With Autoimmune Diseases: A Scoping Review

Clinical Oral Implants Research, EarlyView.
ABSTRACT Objectives The aim of this scoping review is to determine the effects of autoimmune diseases (ADs) and the agents used for treatment on dental implant survival and biologic outcomes. Material and Methods An electronic database search was performed in MEDLINE (PubMed), The Cochrane Library, and Embase on 29‐04‐2024.
Emil Hyldahl, Henning Schliephake, Simon Storgård Jensen   +2 more
wiley   +1 more source

Ulcerative colitis-associated diffuse enteritis without prior colectomy: A case report. [PDF]

Medicine (Baltimore)
He Q, Wei W, Li J, Chen Z, Zhang H.
europepmc   +1 more source

THU0036 The effect of infliximab on plasma lipoproteins [PDF]

, 2001
MM Spak, E Cauza, KC Cauza, UH Hanusch-Enserer, A Dunky, K.M. Kostner   +5 more
openalex   +1 more source